Fibrosis/Cirrhosis
Fibrosis & Cirrhosis
EASL 2013: Triple-Drug HCV Therapy Comes with High Risk of Serious Adverse Events for Cirrhotics
- Details
- Category: HCV Treatment
- Published on Tuesday, 30 April 2013 00:00
- Written by Keith Alcorn
Currently available triple therapies for hepatitis C using HCV protease inhibitors carry a high risk of serious side effects for patients in the most urgent need of treatment, and these individuals have only a moderate chance of being cured, according to findings from studies of telaprevir and boceprevir treatment in cirrhotic patients at liver centers in France and Austria reported last week at the 48th International Liver Congress in Amsterdam. In the Austrian study almost 1 in 10 cirrhotic patients were hospitalized with sepsis during triple therapy.
Hepatitis C Re-treatment with Interferon Monotherapy Provides Little Benefit
- Details
- Category: HCV Treatment
- Published on Wednesday, 06 February 2013 00:00
- Written by Liz Highleyman
Long-term re-treatment with pegylated interferon monotherapy offers little or no clinical benefit -- even though it may suppress hepatitis C virus (HCV) levels and improve liver fibrosis -- but it can cause adverse events and may be associated with higher mortality, according to a systematic review from the Cochrane Library.
Hepatitis C Cirrhosis Patients with Sustained Treatment Response Have Lower Risk of Death
- Details
- Category: HCV Treatment
- Published on Thursday, 27 December 2012 00:00
- Written by Liz Highleyman
Hepatitis C patients with cirrhosis who achieve sustained virological response to interferon-based therapy have a reduced risk of all-cause mortality, liver-related death or transplantation, liver cancer, and liver failure compared with non-responders, according to a study described in the December 26, 2012, issue of JAMA.
HIV+ People Who Get Hepatitis C May Experience Rapid Liver Disease Progression
- Details
- Category: HCV Sexual Transmission
- Published on Tuesday, 08 January 2013 00:00
- Written by Liz Highleyman
People with HIV, especially those with advanced immune suppression, who become coinfected with hepatitis C virus (HCV) may experience rapid progression to decompensated cirrhosis and liver-related death, Mt. Sinai researchers reported in the December 21, 2012, advance edition of Clinical Infectious Diseases.
AASLD 2012: When Are HCV Direct-Acting Antivirals Needed, Who Should Be Prioritized?
- Details
- Category: Liver Cancer/HCC
- Published on Monday, 26 November 2012 00:00
- Written by Rob Camp
When resources for hepatitis C treatment with new direct-acting antivirals are limited, findings from the U.S. suggest that previously untreated people with low HCV viral loads may stand a good chance of achieving sustained virological response without adding telaprevir or boceprevir to pegylated interferon and ribavirin, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this month in Boston. A related study suggests that younger hepatitis C patients with advanced liver disease should be prioritized for treatment with the new drugs. 
More Articles...
- AASLD 2012: Nucleoside Analogs Reduce Hepatitis B Liver Cancer Risk, Cirrhosis Remains a Concern
- AASLD 2012: Telaprevir Twice-daily Works as Well as Every 8 Hours, Safe for Hep C Patients with Cirrhosis
- AASLD 2012: Simeprevir Safe and Effective for Hepatitis C Patients With Cirrhosis
- AASLD 2012: Sofosbuvir + GS-5885 + Ribavirin Shows High Early Response Rates for Genotype 1 HCV
Web Design and Development by